Anticoagulant medication list

An anticoagulant medication list is a clinical reference that groups blood thinners by class, with generic and brand names, routes, monitoring needs and reversal agents. The core classes are warfarin, the direct oral anticoagulants (DOACs), the heparins and fondaparinux. All of them interrupt the coagulation cascade, which sets them apart from antiplatelets such as aspirin.

Practitioners treating atrial fibrillation (AFib), deep vein thrombosis (DVT), pulmonary embolism (PE) and mechanical heart valves use the list to keep prescribing and documentation consistent.

This guide covers each class and how to keep the list current inside the patient record. It also shows how US reversal options for factor Xa inhibitors changed in December 2025.

Key takeaways

Anticoagulants interrupt the coagulation cascade, while antiplatelets block platelet aggregation, so the two classes work by distinct mechanisms.

Warfarin requires INR monitoring, while direct oral anticoagulants (DOACs) don’t need routine coagulation testing.

Specific reversal agents exist for warfarin (vitamin K), dabigatran (idarucizumab) and, in some markets, apixaban and rivaroxaban (andexanet alfa). They’re critical in bleeding emergencies.

Digital forms in Pabau, the practice management platform we build, capture anticoagulation history, current medications, bleeding risk factors and INR targets in one patient record.

What is an anticoagulant medication list?

It’s a reference table that catalogs approved anticoagulants by drug class, mechanism of action and clinical indication. Each entry gives the generic name, brand names and route (oral, injectable or IV). It also records the primary indication, such as AFib, DVT/PE or a mechanical valve. Each entry then notes the monitoring the drug needs (INR, a lab schedule or none).

The list does three jobs:

• Quick lookup for prescribers at the point of decision.
• Patient education, so patients know which blood thinner they take and why.
• Complete documentation for audits and quality reporting.

Anticoagulants work by blocking one or more steps in the coagulation cascade, the series of enzyme reactions that forms a clot. Antiplatelets such as aspirin and clopidogrel work differently. They stop platelets from sticking together and leave the cascade itself untouched.

Types of anticoagulant drugs

Anticoagulants fall into five groups, based on their mechanism and route of administration.

• Vitamin K antagonists (VKAs): Warfarin (Coumadin) is the only VKA in wide use. It blocks the vitamin K-dependent clotting factors II, VII, IX and X, and it requires INR monitoring.
• Direct oral anticoagulants (DOACs, also called NOACs): Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa) and edoxaban each target one point in the cascade. That point is factor Xa or thrombin. Edoxaban is sold as Savaysa in the US and Lixiana in the UK and EU. None of the four needs routine lab monitoring.
• Heparins: Unfractionated heparin (IV) and low-molecular-weight heparin (LMWH, subcutaneous) work through antithrombin III. LMWH options include enoxaparin (Lovenox), dalteparin (Fragmin) and tinzaparin (Innohep), used for acute thrombosis and prophylaxis.
• Selective factor Xa inhibitor: Fondaparinux (Arixtra) is a synthetic pentasaccharide given subcutaneously. It’s used for DVT prophylaxis and acute treatment when heparin is contraindicated.
• Parenteral direct thrombin inhibitors: Argatroban and bivalirudin (Angiomax) are given IV in hospital. They’re used mainly for heparin-induced thrombocytopenia and during percutaneous coronary intervention.

Anticoagulants vs antiplatelets: The critical distinction

Confusing anticoagulants with antiplatelets is a common clinical error, and the mix-up changes what gets prescribed. Anticoagulants block the coagulation cascade and fibrin formation. Antiplatelets inhibit platelet aggregation through the thromboxane A2 or ADP pathway.

Aspirin and clopidogrel (Plavix) are antiplatelets, not anticoagulants. A DOAC can’t be swapped for aspirin in AFib stroke prevention, although aspirin keeps a role after a coronary stent. Keep a separate anti-platelet medication list so the two classes never share a row in the patient record.

How to use the template in five steps

The template walks practitioners through anticoagulant selection, initiation and monitoring. Use it in five steps that match a typical clinical workflow.

1. Identify indication and patient factors: Record why anticoagulation is needed, such as AFib, DVT/PE, a mechanical valve or antiphospholipid syndrome. Then assess renal function, bleeding risk, drug interactions and pregnancy status, and note them in the template’s patient context section.
2. Select the anticoagulant class: Cross-reference indication and patient factors against the template’s class table. For AFib, DOACs are preferred in most patients, and warfarin is used for mechanical valves. For acute DVT/PE, transition to oral agents according to the chosen drug. Warfarin overlaps with heparin for at least five days and until INR is in range. Dabigatran and edoxaban follow 5 to 10 days of parenteral therapy. Apixaban and rivaroxaban start with their own loading doses.
3. Document monitoring parameters: Warfarin requires INR monitoring, with a target range of 2.0 to 3.0 for most indications. DOACs need no routine coagulation testing but do need periodic renal function checks. The template lists monitoring intervals and thresholds for each drug.
4. Record reversal agent availability: The template’s reversal lookup gives vitamin K for warfarin and idarucizumab (Praxbind) for dabigatran. For apixaban and rivaroxaban, it gives andexanet alfa (Andexxa) where available (withdrawn from the US market in December 2025; still available in the UK/EU). Four-factor prothrombin complex concentrate (4F-PCC) is the alternative for factor Xa inhibitors. Keep the lookup visible during the episode of care.
5. Add it to the clinical record: Attach the completed template to the patient’s record with Pabau’s digital intake forms. Anticoagulation history, current dosing, target INR and reversal plans are then on hand at every visit.

Who uses the list

Primary care practices managing AFib, cardiologists treating acute thrombosis and anticoagulation management services all rely on a structured list. Nurse practitioners and physician assistants in hospital anticoagulation clinics use it for protocol consistency.

Medical directors of multi-location practices use one standardized list, so every prescriber follows the same drug-monitoring framework. That reduces prescribing errors and improves documentation audit scores.

Medical weight loss programs need it too, because obesity raises the risk of AFib and some patients arrive already taking a blood thinner. For those programs, weight loss practice software can hold the anticoagulant entry on the same record as the treatment plan.

Why a shared list cuts prescribing errors

A structured list reduces prescribing errors by putting drug names, routes and monitoring thresholds in one document. It also supports compliance. The Joint Commission’s National Patient Safety Goal NPSG.03.05.01 requires documented anticoagulation management processes, and an auditable template strengthens inspection readiness.

Anticoagulants also sit on the ISMP list of high-alert medications, so this list pairs naturally with a high-alert medication list.

Documentation improves when the template captures INR targets, baseline renal function and reversal agents up front. Those fields then carry through every clinical note. For multi-location practices, one shared template keeps every practitioner on the same class protocols and monitoring intervals. That cuts variation and liability exposure.

Anticoagulant side effects and bleeding risks

Major adverse events with anticoagulants center on bleeding. Warfarin interacts with vitamin K (in diet and medications) and many drugs, and NSAIDs and aspirin add to bleeding risk. Interacting drugs can raise INR unpredictably. DOACs have fewer food-drug interactions but carry similar bleeding hazards, especially in older patients or those with renal impairment.

Patients buy NSAIDs and aspirin without a prescription, so check their OTC medication list at every review. Minor bleeding, such as nosebleeds and easy bruising, is common. Major bleeding (gastrointestinal, intracranial or retroperitoneal) is rare but life-threatening.

Reversal options must be immediately available when major bleeding occurs. They include vitamin K for warfarin and idarucizumab for dabigatran. For apixaban and rivaroxaban, andexanet alfa is used where available (withdrawn from the US market in December 2025; still available in the UK/EU). Otherwise, 4F-PCC is the alternative for factor Xa inhibitors, including edoxaban, which has no specific reversal agent.

The reversal route for the same bleed now depends on which side of the Atlantic the patient is treated, as the chart below shows.

How Pabau keeps anticoagulation details in the patient record

Plenty of practices still keep the anticoagulant list on paper or in a shared drive, apart from the patient file. When a patient on apixaban books a procedure, someone has to find that list, check the dose and confirm when the drug was last held.

Pabau keeps the anticoagulant, dose, INR target and reversal plan in structured patient records. Every clinician on the team sees the current regimen, which matters most during emergencies, transitions of care and pre-procedure checks.

Pabau Scribe, our AI scribe, can draft notes from the consultation, which the practitioner reviews before saving to the patient record. Patients can also complete a medication history form before the visit, and their answers flow into the same record.

Anticoagulation records hold sensitive medication and clinical information, so HIPAA and data protection rules apply. Choose a system that encrypts data at rest and in transit, logs access and keeps audit trails. Confirm Pabau’s security documentation with our team before you move patient data across.

Keep anticoagulation plans on the patient record

Pabau stores anticoagulation history, INR targets and reversal plans in one patient record, so prescribers see them before a procedure or a bleed. Book a demo to see it set up for your practice.

Book a demo

Conclusion

An anticoagulant medication list proves its worth before a procedure, during a bleed or at a handoff between clinicians. Those are the moments when a missing reversal plan costs time.

Start by checking that every patient record keeps anticoagulants and antiplatelets apart. Then confirm each entry names its reversal agent and monitoring rule, including whether that agent is available in your market. Those two fields address the mix-ups and delays this guide warns about.

The trade-off is upkeep. US reversal options changed in December 2025, and a printed list goes stale as guidance moves, so review it on a fixed schedule. Keeping it inside the patient record turns that review into one update rather than a hunt through paper copies. Book a demo to see how Pabau keeps anticoagulation history, INR targets and reversal plans together in one patient record.

Continue your research

Need the other half of the antithrombotic picture? Anti platelet medication list covers aspirin, clopidogrel, and the other agents patients often confuse with anticoagulants.

Managing patients on several heart medications? Cardiovascular medication list groups the main cardiac drug classes in one reference for prescribers.

Reviewing statins alongside blood thinners? Cholesterol medication list sets out lipid-lowering drugs by class for medication reviews.

Checking blood pressure medicines at the same visit? Free medication list of ACE inhibitors lists the ACE inhibitors used for hypertension and heart failure.

Double-checking your riskiest prescriptions? High-alert medication list flags the medicines, anticoagulants among them, that cause the most harm when an error slips through.

Frequently asked questions